Tag

Salute_E_Benessere Chimica_E_Farmacia Chimica_E_Farmacia Altro

1 minuto di lettura

Verismo Therapeutics Announces Upcoming Presentation at SITC 2023

(Adnkronos) – PHILADELPHIA, Nov. 3, 2023 /PRNewswire/ — Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology today announced that it will be presenting at the upcoming Society for Immunotherapy

Immediapress

Nippon Express Italia Obtains IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport

(Adnkronos) – TOKYO, May 11, 2023 /PRNewswire/ — Nippon Express Italia S.p.A. (hereinafter “NX Italia”), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association (IATA), for

EirGenix’s Breast Cancer Biosimilar Receives Marketing Authorization by EC

Immediapress

(Adnkronos) – TAIPEI, Nov. 23, 2023 /PRNewswire/ — EirGenix Inc. (6589. TT) announced today that its trastuzumab biosimilar medicine (EG12014) which their commercial partner

EirGenix’s Breast Cancer Biosimilar Receives Marketing Authorization by EC

Immediapress

(Adnkronos) – TAIPEI, Nov. 23, 2023 /PRNewswire/ — EirGenix Inc. (6589. TT) announced today that its trastuzumab biosimilar medicine (EG12014) which their commercial partner

Norgine accoglie con favore il parere positivo del CHMP che raccomanda l’approvazione di mavorixafor nell’Unione europea per la sindrome WHIM

sabato, 28 Febbraio 2026

Immediapress

La raccomandazione del CHMP segna un passo importante verso il primo trattamento autorizzato per la sindrome WHIM in EuropaLa decisione finale della Commissione europea è prevista per il secondo trimestre del 2026

Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome

venerdì, 27 Febbraio 2026

Immediapress

CHMP recommendation marks major step toward first authorised treatment for WHIM syndrome in EuropeFinal decision expected from the European Commission in Q2 2026 Partnership with X4 Pharmaceuticals for Norgine-led commercialisation in Europe AMSTERDAM,

Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome

venerdì, 27 Febbraio 2026

Immediapress

Salute_E_Benessere Chimica_E_Farmacia Chimica_E_Farmacia Altro

Verismo Therapeutics Announces Upcoming Presentation at SITC 2023

Nippon Express Italia Obtains IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport

EirGenix’s Breast Cancer Biosimilar Receives Marketing Authorization by EC

EirGenix’s Breast Cancer Biosimilar Receives Marketing Authorization by EC

Norgine accoglie con favore il parere positivo del CHMP che raccomanda l’approvazione di mavorixafor nell’Unione europea per la sindrome WHIM

Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome

Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome

Primo piano

CdM approva decreto urgente per autotrasporto, agricoltura e pesca. Meloni: “Non tolleriamo intimidazioni” | Video

Il prete che ha mostrato il dito medio ai ragazzi durante i disordini a Milano: «Pentito? No, ho solo risposto»

Italia-Spagna, la sospensione di Schengen non sarà rinnovata

Blocco Tir, governo “sblocca” in Sicilia e Calabria, ma il Golfo di Napoli a rischio isolamento

Dopo gli scontri: cosa prevede il decreto e quali poteri hanno i militari

Sponsor

Suggerimenti

Salute_E_Benessere Chimica_E_Farmacia Chimica_E_Farmacia Altro

Primo piano

Sponsor